FLT3 and acute myeloid leukemia: FLT3-ITD mutant AML was significantly associated with shorter RFS in the whole study population (5 months) and in a group of CN-AML (1 month), however, the different of RFS between FLT3-ITD mutation (15 months) and wild type FLT3-ITD (18 months) was not significant in the group of patients with completed consolidation therapy, that might be from small number of our AML patients with mutant FLT3-ITD who had completed consolidation chemotherapy.